Cyta Therapeutics

2:00 PM - 4:00 PM (EDT), Wednesday, June 7, 2023 ・ North Lobby
Cyta Therapeutics is a pre-clinical company developing therapies for cardiometabolic diseases. Cyta’s lead clinical candidate is a liver targeted nanoparticle encapsulating a thyromimetic for the treatment of obesity and other cardiometabolic syndromes. Cyta’s lead clinical candidate has demonstrated 28% weight loss in the diet-induced obesity-NASH (DIO-NASH) mouse model. Results also showed lowered cholesterol and triglycerides, reduction of fatty liver/steatosis and improvement of insulin sensitivity. There was no lowering of T4 levels suggesting no peripheral side effects due to the liver targeting of the nanoparticle delivery system. Short-term (1 month) toxicity studies have not generated any safety concerns. Cyta 's lead clinical candidate is two years away from IND submission. The company was co-founded by Professor Thayumanavan of UMass, Amherst, CEO, Bonnie Fendrock, MS, MBA, a biotech leader (Genzyme), and entrepreneur (Hepregen), and CSO, Steve Faraci, PhD, a pharmaceutical development leader (Pfizer). Cyta has filed IP on the lead clinical candidate and has an exclusive option to the platform delivery technology developed by Professor Thayumanavan.
Placeholder Photo
Cyta Therapeutics